Patents Assigned to Genentech
  • ISOQUINOLINE AND NAPHTHYRIDINE DERIVATIVES
    Publication number: 20140343036
    Abstract: The invention provides novel compounds having the general formula: wherein A, R1 and R2 are as described herein, compositions including the compounds and methods of using the compounds.
    Type: Application
    Filed: July 31, 2014
    Publication date: November 20, 2014
    Applicant: GENENTECH, INC.
    Inventors: Huifen Chen, Terry Crawford, Steven R. Magnuson, Chudi Ndubaku, Lan Wang
  • THERAPEUTIC COMBINATIONS AND METHODS OF TREATING MELANOMA
    Publication number: 20140341916
    Abstract: The invention provides therapeutic combinations of anti-ETBR antibodies and MAP kinase inhibitors and methods of using the same to treat melanoma.
    Type: Application
    Filed: October 24, 2012
    Publication date: November 20, 2014
    Applicant: GENENTECH, INC.
    Inventors: Paul Polakis, Jyoti Asundi, Suzanna Clark
  • METHODS OF TREATING CANCER USING PD-1 AXIS BINDING ANTAGONISTS AND MEK INHIBITORS
    Publication number: 20140341902
    Abstract: The present invention describes combination treatment comprising a PD-1 axis binding antagonist and a MEK inhibitor and methods for use thereof, including methods of treating conditions where enhanced immunogenicity is desired such as increasing tumor immunogenicity for the treatment of cancer.
    Type: Application
    Filed: August 1, 2012
    Publication date: November 20, 2014
    Applicant: Genentech, Inc.
    Inventors: Heather Maecker, Bryan Irving
  • TREATMENT WITH ANTI ErbB2 ANTIBODIES
    Publication number: 20140341886
    Abstract: The present invention concerns the treatment of disorders characterized by the overexpression of ErbB2. More specifically, the invention concerns the treatment of human patients susceptible to or diagnosed with cancer overexpressing ErbB2 with a combination of an anti-ErbB2 antibody and a chemotherapeutic agent other than an anthracycline, e.g. doxorubicin or epirubicin. The invention further provides a method of treating cancer in a human patient comprising administering effective amounts of an anti-ErbB2 antibody and a cardioprotectant to the patient.
    Type: Application
    Filed: December 26, 2013
    Publication date: November 20, 2014
    Applicant: Genentech, Inc.
    Inventor: Susan D. Hellmann
  • METHODS FOR TREATING, DIAGNOSING, AND MONITORING RHEUMATOID ARTHRITIS
    Publication number: 20140341887
    Abstract: Methods of identifying, diagnosing, and prognosing rheumatoid arthritis are provided, as well as methods of treating rheumatoid arthritis. Also provided are methods for identifying effective rheumatoid arthritis therapeutic agents and predicting responsiveness to rheumatoid arthritis therapeutic agents.
    Type: Application
    Filed: April 8, 2014
    Publication date: November 20, 2014
    Applicant: GENENTECH, INC.
    Inventors: Glynn DENNIS, JR., Flavius MARTIN, Michael J. TOWNSEND
  • Triazolopyridine JAK inhibitor compounds and methods
    Patent number: 8889673
    Abstract: A compound of Formula I, enantiomers, diasteriomers, tautomers or pharmaceutically acceptable salts thereof, wherein R1, R2, R3, R4 and R5 are defined herein, are useful as JAK kinase inhibitors. A pharmaceutical composition that includes a compound of Formula I and a pharmaceutically acceptable carrier, adjuvant or vehicle, and methods of treating or lessening the severity of a disease or condition responsive to the inhibition of JAK kinase activity in a patient are disclosed.
    Type: Grant
    Filed: June 21, 2012
    Date of Patent: November 18, 2014
    Assignee: Genentech, Inc.
    Inventors: Bing-Yan Zhu, Michael Siu, Steven R. Magnuson, Richard Pastor, He Haiying, Xiao Yisong, Zheng Jifu, Xu Xing, Zhao Junping, Wendy Liu
  • Antibodies and immunoconjugates and uses therefor
    Patent number: 8889847
    Abstract: Anti-STEAP-1 antibodies and immunoconjugates thereof are provided. Methods of using anti-STEAP-1 antibodies and immunoconjugates thereof are provided.
    Type: Grant
    Filed: February 13, 2013
    Date of Patent: November 18, 2014
    Assignee: Genentech, Inc.
    Inventors: Mark S. Dennis, Bonnee Rubinfeld, Paul Polakis, Aya Jakobovits
  • Use Of Complement Inhibitors To Treat Ocular Diseases
    Publication number: 20140335078
    Abstract: The present invention relates to the treatment of ocular diseases and conditions by administering a complement pathway inhibitor, particularly an alternative pathway inhibitor. Ocular diseases include age-related macular degeneration, diabetic retinopathy, and ocular angiogenesis. One embodiment comprises the administration of an anti-Factor D antibody in the form of a whole antibody, a Fab fragment or a single domain antibody. Other complement component inhibitors that may be useful in the present method include Factor H or inhibitors that block the action of properdin, factor B, factor Ba, factor Bb, C2, C2a, C3a, C5, C5a, C5, C6, C7, C8, C9, or C5b-9.
    Type: Application
    Filed: May 6, 2014
    Publication date: November 13, 2014
    Applicant: Genentech, Inc.
    Inventors: Sek Chung Fung, Zhengbin Yao
  • ASSEMBLY OF BISPECIFIC ANTIBODIES
    Publication number: 20140336361
    Abstract: Described herein are methods for the efficient production of a heteromultimeric protein, such as a bispecific antibody. Heteromultimeric proteins may be capable of specifically binding to more than one target molecule or different epitopes on a single target molecule. The methods modulate parameters to improve assembly of the heteromultimeric proteins at higher yield and efficiency than otherwise possible. Also described are compositions comprising a hinge-containing polypeptide, such as a half-antibody.
    Type: Application
    Filed: April 11, 2014
    Publication date: November 13, 2014
    Applicant: GENENTECH, INC.
    Inventors: GLEN GIESE, AMY LIM, JOSEFINE PERSSON, JUSTIN SCHEER, AMBROSE WILLIAMS
  • ANTI-CD79B ANTIBODIES AND IMMUNOCONJUGATES AND METHODS OF USE
    Publication number: 20140335107
    Abstract: The present invention is directed to compositions of matter useful for the treatment of hematopoietic tumor in mammals and to methods of using those compositions of matter for the same.
    Type: Application
    Filed: March 19, 2014
    Publication date: November 13, 2014
    Applicant: GENENTECH, INC.
    Inventors: Yvonne Chen, Mark Dennis, David Dornan, Kristi Elkins, Jagath Reddy Junutula, Andrew Polson
  • Tricyclic PI3K inhibitor compounds and methods of use
    Patent number: 8883799
    Abstract: Tricyclic PI3k inhibitor compounds of Formula I with anti-cancer activity, anti-inflammatory activity, or immunoregulatory properties, and more specifically with PI3 kinase modulating or inhibitory activity are described. Methods are described for using the tricyclic PI3K inhibitor compounds of Formula I for in vitro, in situ, and in vivo diagnosis or treatment of mammalian cells, organisms, or associated pathological conditions. Formula I compounds include stereoisomers, geometric isomers, tautomers, and pharmaceutically acceptable salts thereof. The dashed lines indicate an optional double bond, and at least one dashed line is a double bond. The substituents are as described.
    Type: Grant
    Filed: December 15, 2011
    Date of Patent: November 11, 2014
    Assignee: Genentech, Inc.
    Inventors: Jennafer Dotson, Robert Andrew Heald, Timothy Heffron, Graham Elgin Jones, Sussie Lerche Krintel, Neville James McLean, Chudi Ndubaku, Alan G. Olivero, Laurent Salphati, Lan Wang, BinQing Wei
  • MODULATION OF AXON DEGENERATION
    Publication number: 20140328940
    Abstract: The invention relates generally to treatment of neurological disorders and nervous system injuries. The invention specifically provides methods of using modulators of particular target proteins to modulate degeneration of neurons or portions thereof, such as axons.
    Type: Application
    Filed: December 20, 2013
    Publication date: November 6, 2014
    Applicant: Genentech, Inc.
    Inventors: Joseph W. LEWCOCK, Christine Pozniak, Arundhati Sengupta-Ghosh
  • BIHETEROARYL COMPOUNDS AND USES THEREOF
    Publication number: 20140328805
    Abstract: The present invention provides for compounds of Formula I and embodiments and salts thereof for the treatment of diseases (e.g., neurodegenerative diseases). R1, R2, R3, X1, X2, A and Cy variable in Formula all have the meaning as defined herein.
    Type: Application
    Filed: May 1, 2014
    Publication date: November 6, 2014
    Applicant: GENENTECH, INC.
    Inventors: Anthony Estrada, Alan G. Olivero, Snahel Patel, Michael Siu
  • ANTI-CRTH2 ANTIBODIES AND METHODS OF USE
    Publication number: 20140328849
    Abstract: The invention provides anti-CRTh2 antibodies and methods of using the same.
    Type: Application
    Filed: March 14, 2014
    Publication date: November 6, 2014
    Applicant: GENENTECH, INC.
    Inventors: Karin REIF, Isidro HOTZEL, Jo-Anne S. HONGO, Tao HUANG, Yonglei SHANG, Meredith HAZEN
  • Compositions and methods for the diagnosis and treatment of tumor
    Patent number: 8877897
    Abstract: The present invention is directed to compositions of matter useful for the diagnosis and treatment of tumor in mammals and to methods of using those compositions of matter for the same.
    Type: Grant
    Filed: February 22, 2011
    Date of Patent: November 4, 2014
    Assignee: Genentech, Inc.
    Inventors: Paul Polakis, Jyoti Asundi, Ron Firestein, Robert F. Kelley, Krista McCutcheon
  • FORMULATIONS WITH REDUCED OXIDATION
    Publication number: 20140322203
    Abstract: The invention provides formulations comprising a protein in combination with a compound that prevents oxidation of the protein. The invention also provides methods for making such formulations and methods of using such formulations. The invention further provides methods of screening for compounds that prevent oxidation of a protein in a protein composition and methods of preventing oxidation of a protein in a formulation.
    Type: Application
    Filed: March 13, 2014
    Publication date: October 30, 2014
    Applicant: GENENTECH, INC.
    Inventors: Sreedhara ALAVATTAM, Mary MALLANEY, Parbir GREWAL
  • MULTIVALENT ANTIBODIES AND USES THEREFOR
    Publication number: 20140322221
    Abstract: The present application describes engineered antibodies, with three or more functional antigen binding sites, and uses, such as therapeutic applications, for such engineered antibodies.
    Type: Application
    Filed: March 28, 2014
    Publication date: October 30, 2014
    Applicant: Genentech, Inc.
    Inventors: Kathy L. MILLER, Leonard G. PRESTA
  • ANTI-B7-H4 ANTIBODIES AND IMMUNOCONJUGATES
    Publication number: 20140322129
    Abstract: The invention provides anti-B7-H4 antibodies and immunoconjugates and methods of using the same.
    Type: Application
    Filed: March 13, 2014
    Publication date: October 30, 2014
    Applicant: Genentech, Inc.
    Inventors: Steven R. Leong, Andrew Polson, Paul Polakis, Yan Wu, Wei-Ching Liang, Ron Firestein
  • TREATMENT WITH ANTI ErbB2 ANTIBODIES
    Publication number: 20140322202
    Abstract: The present invention concerns the treatment of cancer with anti-ErbB2 antibodies.
    Type: Application
    Filed: December 26, 2013
    Publication date: October 30, 2014
    Applicant: Genentech, Inc.
    Inventor: Robert L. Cohen
  • SERINE/THREONINE KINASE INHIBITORS
    Publication number: 20140323477
    Abstract: Compounds having the formula I, or a pharmaceutically acceptable salt thereof, wherein R1, R2, X1, X2, and Ar are as defined herein, are inhibitors of PAK1. Also disclosed are compositions and methods for treating cancer and hyperproliferative disorders using such compounds.
    Type: Application
    Filed: April 30, 2014
    Publication date: October 30, 2014
    Applicant: GENENTECH, INC.
    Inventors: James J. CRAWFORD, Wendy LEE, Joachim RUDOLPH